Ticagrelor-induced acute generalized exanthematous pustulosis

Maybrook, Ryan; Deibert, Brent; Gillihan, Ryan; Laarman, Rachel; Fraga, Garth; Aires, Daniel; Gollub, S

doi:10.1016/j.ijcard.2015.04.264

Cited by 8 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The case reported by Quinn et al demonstrated very similar skin biopsy findings showing perivascular lymphocytic infiltrates compared to our patient but did not comment on necrotic keratinocytes as seen in our biopsy [3]. The four other reports showed different dermatological reactions with one case of exanthematous pustulosis [5], one case of eccrine hidradenitis [6], one case of a bullous fixed drug eruption [7], and a case of Sweet syndrome [8]. These cases are described in Table 1.…”

Section: Discussionsupporting

confidence: 80%

Generalized Drug Eruption Secondary to Ticagrelor: A Case Report and Review of the Literature

Akdogan¹,

Chen²,

Varón³

et al. 2023

Cureus

View full text Add to dashboard Cite

Currently, guidelines recommend ticagrelor over clopidogrel as part of dual antiplatelet therapy with aspirin in treating individuals with acute coronary syndrome. As there is an increased usage of ticagrelor, it is important to keep in mind uncommon adverse events, including hypersensitivity skin reactions. To date, only a few studies have been published regarding ticagrelor-induced skin eruptions. Additionally, there is no consensus on antiplatelet therapy management after a hypersensitivity reaction to antiplatelet agents. Hereinafter, we describe a case of an 81-year-old female who presents with a diffuse erythematous hypersensitivity eruption, including palms and soles, secondary to ticagrelor use. Ticagrelor transitioned to clopidogrel, and the patient was started on steroid taper with an antihistamine. The patient's rash progressively improved after the treatment. Our case demonstrates a rare adverse effect of ticagrelor, which needs prompt diagnosis and switching to one of the thienopyridines to prevent thrombosis.

show abstract

Section: Discussionsupporting

confidence: 80%

Generalized Drug Eruption Secondary to Ticagrelor: A Case Report and Review of the Literature

Akdogan¹,

Chen²,

Varón³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Progression of the psoriatic skin lesions in the recruited patients was not monitored, but the study indicates that vascular inflammation in psoriasis can be improved by targeting platelets (Habets et al, 2013). Other systemic antiplatelet medications such as P2Y12 antagonists (clopidogrel or prasugrel) have tolerable dermatological side effects (Hewitt et al, 2018;Kawasaki-Nagano et al, 2019;Maybrook et al, 2015;Nakamizo et al, 2010) and should be explored to treat simultaneously CVD and psoriasis skin manifestations. A similar dual mechanism of action may apply to the immunosuppressive methotrexate (Prodanovich et al, 2005) and current biological agents (Elnabawi et al, 2019).…”

Section: Therapeutic Implications and Future Perspectivesmentioning

confidence: 99%

Platelets: Underestimated Regulators of Autoinflammation in Psoriasis

Herster

Karbach

Chatterjee

et al. 2021

Journal of Investigative Dermatology

View full text Add to dashboard Cite

“…Direct oral anticoagulants, including apixaban and dabigatran, as well as non-oral anticoagulants, namely enoxaparin, have been reported a few times in the literature [ 105 – 109 ]. Diabetes medications, including DPP-4 inhibitors (linagliptin) and sulfonylureas (gliclazide), have been reported as implicated in AGEP [ 110 , 111 ].…”

Section: Pathogenesismentioning

confidence: 99%

Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management

et al. 2023

View full text Add to dashboard Cite

Acute generalized exanthematous pustulosis (AGEP) is a rare, acute, severe cutaneous adverse reaction mainly attributed to drugs, although other triggers, including infections, vaccinations, ingestion of various substances, and spider bites, have also been described. AGEP is characterized by the development of edema and erythema followed by the eruption of multiple punctate, non-follicular, sterile pustules and subsequent desquamation. AGEP typically has a rapid onset and prompt resolution within a few weeks. The differential diagnoses for AGEP are broad and include infectious, inflammatory, and drug-induced etiologies. Diagnosis of AGEP depends on both clinical and histologic criteria, as cases of overlap with other disease processes have been reported. Management includes removal of the offending drug or treatment of the underlying cause, if necessary, and supportive care, as AGEP is a self-limited disease. This review aims to provide an overview and update on the epidemiology, pathogenesis, reported precipitating factors, differentials, diagnosis, and management of AGEP.

show abstract

Ticagrelor-induced acute generalized exanthematous pustulosis

Cited by 8 publications

References 8 publications

Generalized Drug Eruption Secondary to Ticagrelor: A Case Report and Review of the Literature

Generalized Drug Eruption Secondary to Ticagrelor: A Case Report and Review of the Literature

Platelets: Underestimated Regulators of Autoinflammation in Psoriasis

Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management

Contact Info

Product

Resources

About